RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
Antiglaucoma Agent
| Parameter | Detail |
| Starting dose | 1 drop in affected eye(s) three times daily |
| Titration | Not applicable — fixed dosing regimen |
| Usual maintenance dose | 1 drop in affected eye(s) three times daily |
| Maximum dose | 1 drop TID; do not exceed this frequency |
| Duration |
Short-term only — limit to a maximum of 30 days
|
| Key clinical notes | Tachyphylaxis (loss of IOP-lowering effect) commonly develops within 1 month. Not suitable for long-term monotherapy. Reassess IOP response within 1–2 weeks. If inadequate response or tolerance develops, switch to alternative agents. |
| Parameter | Detail |
| Pre-procedure dose | 1 drop in the operative eye, approximately 1 hour before the laser procedure |
| Post-procedure dose | 1 drop in the same eye immediately upon completion of the procedure |
| Titration | Not applicable — single pre- and post-procedure use |
| Usual maintenance dose | Not applicable (peri-procedural use only) |
| Maximum dose | 2 drops total (1 pre + 1 post per procedure per eye) |
| Key clinical notes | Effectively blunts the acute IOP spike that commonly occurs within 1–4 hours post-laser. Not intended for continued use beyond the day of the procedure. |
| Parameter | Detail |
| Minimum age | Not recommended below 6 years of age (risk of significant systemic absorption and CNS depression in younger children) |
| Starting dose | 1 drop of 0.5% solution in affected eye(s) two to three times daily |
| Titration | Not applicable |
| Usual maintenance dose | 1 drop TID |
| Maximum dose | 1 drop TID; do not exceed 30 days of continuous use |
| Safety monitoring | Monitor for systemic effects at each visit: somnolence, lethargy, bradycardia, hypotension, pallor, hypothermia. Check heart rate and blood pressure at baseline and within 1 week of starting. |
| Severity | Recommendation |
| Mild impairment | No dose adjustment required |
| Moderate impairment | No dose adjustment required; use with routine monitoring |
| Severe impairment | Use with caution — although systemic absorption is low, clonidine-like compounds undergo hepatic metabolism; monitor for any systemic effects (hypotension, bradycardia) |
| Parameter | Detail |
| Overall safety | Insufficient human data; avoid during pregnancy unless benefit clearly outweighs risk |
| Teratogenicity | No adequate human studies; animal data limited |
| Preferred alternatives in Indian practice | Topical timolol (most clinical experience in pregnancy for IOP control); topical dorzolamide may be considered in 2nd/3rd trimester. Avoid prostaglandin analogues (theoretical risk of uterine contractions) |
| When it may be used | Only if other approved topical agents fail or are contraindicated; ophthalmologist and obstetrician joint decision |
| What to monitor | Maternal blood pressure and heart rate; fetal heart rate monitoring if chronic use is unavoidable |
| Parameter | Detail |
| Compatibility | Caution advised — insufficient data on excretion into human breast milk |
| Expected drug levels in milk | Expected to be low (minimal systemic absorption from topical ocular route) |
| Preferred alternatives | Topical timolol (more data available in lactation, though infant monitoring still needed); topical dorzolamide or brinzolamide may be considered |
| What to monitor in infant | Sedation, lethargy, poor feeding, bradycardia, hypotonia |
| Note | Brimonidine should be used with caution during breastfeeding as it may cause infant CNS depression — not necessarily a safer choice than apraclonidine in this setting |
| Interacting Drug/Class | Effect / Risk | Action |
|
MAOIs (phenelzine, isocarboxazid, tranylcypromine, selegiline at high doses)
|
Risk of severe hypertensive crisis or potentiation of CNS effects |
Contraindicated — do NOT combine
|
|
Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline)
|
May blunt the IOP-lowering and hypotensive effect of apraclonidine; unpredictable cardiovascular response |
Avoid combination if possible; if co-prescribed, monitor IOP response closely
|
|
Systemic clonidine or other centrally-acting alpha-2 agonists (methyldopa, tizanidine)
|
Additive systemic hypotension, bradycardia, and CNS depression |
Avoid concurrent use unless under close monitoring
|
|
Opioids, benzodiazepines, or other potent CNS depressants
|
Additive sedation and CNS depression, particularly in elderly or paediatric patients |
Use with caution; monitor for excessive sedation
|
| Interacting Drug/Class | Effect / Risk | Action |
| Topical or systemic beta-blockers (timolol, atenolol, metoprolol) | Additive IOP-lowering (beneficial) but also additive risk of bradycardia and hypotension | Monitor heart rate and blood pressure; combination is commonly used in ophthalmology but warrants vigilance |
| Systemic antihypertensive agents (ACE inhibitors, ARBs, calcium channel blockers) | Potential synergistic hypotensive effect due to alpha-2 agonist activity | Monitor blood pressure, especially during initial days of combination |
| Cardiac glycosides (digoxin) | Apraclonidine-induced bradycardia may be additive with digoxin effect on AV conduction | Monitor heart rate |
| Topical ophthalmic agents with preservatives | Additive ocular surface irritation if multiple preserved drops are used concurrently | Space administration by at least 5 minutes between different eye drops |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.